Virginia Commonwealth University

Running trials

• Not yet recruiting

  Young Adult-Mediated Intervention to Increase Colorectal Cancer Screening

  NCT05936931· Virginia Commonwealth University· Source

• Not yet recruiting

  Bedside Cranial Ultrasound for Risk-Stratified Imaging in Pediatric Acute Brain Injury

  NCT07772323· Virginia Commonwealth University· Source

• Not yet recruiting

  Southeastern ATTR Amyloidosis Consortium: SEATTRAC Family Registry

  NCT05974644· Virginia Commonwealth University· Source

• Recruiting

  Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension

  NCT07700225· Virginia Commonwealth University· Source

• Recruiting

  Open-label Feasibility Trial of HD-tDCS During Cognitive Behavioral Therapy for Cocaine Use Disorder

  NCT07829263· Virginia Commonwealth University· Source

• Recruiting

  Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN

  NCT07710534· Phase 2· Virginia Commonwealth University· Source

• Not yet recruiting

  Rethinking Early Airway Clearence Therapies

  NCT07696338· Nicole Hamblett· Source

• Not yet recruiting

  Colon Health Champion Program

  NCT07796334· Virginia Commonwealth University· Source

• Not yet recruiting

  Transcranial Doppler Evaluation After Endovascular Thrombectomy for Acute Ischemic Stroke (PRECISE-TCD)

  NCT07013396· Virginia Commonwealth University· Source

• Not yet recruiting

  Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior Chemotherapy

  NCT07639086· Phase 2· Virginia Commonwealth University· Source

• Recruiting

  Autonomic and Renal Contributions to Hypertension With ADT

  NCT07848828· Phase 4· Virginia Commonwealth University· Source

• Recruiting

  Cryoablation for Monomorphic Ventricular Tachycardia (VTS)

  NCT07650032· Adagio Medical· Source

• Recruiting

  My Path to Quit Tobacco

  NCT07419425· Phase 4· University of Wisconsin, Madison· Source

• Recruiting

  The HOPE Biobank Resource (BMT CTN 2402 HOPE)

  NCT07227155· Medical College of Wisconsin· Source

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV

  NCT07143968· Phase 2· Naga P. Chalasani· Source

• Recruiting

  A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout

  NCT07388498· Phase 3· Amgen· Source

• Recruiting

  Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

  NCT07224360· Phase 2· CSL Behring· Source

• Recruiting

  Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

  NCT07227298· Phase 1/2· Pfizer· Source

• Recruiting

  A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  NCT07063745· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia

  NCT07284290· Phase 4· Virginia Commonwealth University· Source

• Recruiting

  Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis

  NCT06794229· Phase 2· Qian Qin· Source

• Enrolling by invitation

  Novel On-body Evaluation of Cardiac Health for Oncology

  NCT07158450· Skribe Medical· Source

• Recruiting

  A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  NCT06989437· Phase 2/3· Pfizer· Source

• Recruiting

  Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

  NCT06745908· Phase 3· ImmunityBio, Inc.· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  NCT07144280· Phase 3· Pfizer· Source

• Recruiting

  Enhancing Oral Cancer Awareness

  NCT06682494· Virginia Commonwealth University· Source

• Recruiting

  Randomized Controlled Trial of Treatment to Optimize Heart Rate Variability for Persistent Post-Concussion Symptoms

  NCT07071350· Phase 2/3· Virginia Commonwealth University· Source

• Recruiting

  Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator

  NCT06964464· Phase 4· University of Rochester· Source

• Recruiting

  Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

  NCT06911632· Tempus AI· Source

• Active, not recruiting

  P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

  NCT06468033· Phase 3· PharmaEssentia· Source

• Recruiting

  The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study

  NCT06854458· Brigham and Women's Hospital· Source

• Enrolling by invitation

  Global Open-Label Extension Study of Del-desiran for the Treatment of DM1

  NCT07008469· Phase 3· Avidity Biosciences, Inc.· Source

• Recruiting

  FearLess in NeuroOncology

  NCT06989086· Virginia Commonwealth University· Source

• Recruiting

  Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

  NCT06846281· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

  NCT06944522· Phase 3· BlueRock Therapeutics· Source

• Recruiting

  Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension

  NCT06747884· Virginia Commonwealth University· Source

• Recruiting

  Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+

  NCT06846463· Phase 2· Virginia Commonwealth University· Source

• Recruiting

  Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

  NCT06563895· Phase 3· Eidos Therapeutics, a BridgeBio company· Source

• Recruiting

  Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain

  NCT06374238· University of Pittsburgh· Source

• Recruiting

  Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer

  NCT06728072· Phase 2· Virginia Commonwealth University· Source

• Recruiting

  GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy

  NCT06636123· Phase 1· Virginia Commonwealth University· Source

• Recruiting

  Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)

  NCT06731413· Phase 2· Virginia Commonwealth University· Source

• Recruiting

  Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

  NCT06712355· Phase 3· BioNTech SE· Source

• Recruiting

  DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

  NCT06388421· United Therapeutics· Source

• Recruiting

  SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

  NCT06743126· Phase 3· Immatics US, Inc.· Source

• Recruiting

  A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

  NCT06562543· Phase 4· Takeda· Source

• Recruiting

  EXercise Cardiac Magnetic Resonance Assessment of Left Atrial Mechanics Following Ablation

  NCT06212791· Virginia Commonwealth University· Source

• Recruiting

  Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

  NCT06660355· Phase 2· H. Lee Moffitt Cancer Center and Research Institute· Source

• Recruiting

  Safety and Effectiveness of Valbenazine as Adjunct Therapy to Botulinum Toxin Injections in Cervical Dystonia

  NCT06771323· Phase 2· Virginia Commonwealth University· Source

Showing 50 of 168.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure11 recruiting
• Lung cancer9 recruiting
• Childhood cancers7 recruiting
• Myotonic dystrophy7 recruiting
• Acute myeloid leukaemia4 recruiting
• Amyloidosis4 recruiting
• Colorectal cancer4 recruiting
• Cystic fibrosis4 recruiting
• Fatty liver disease (MASLD/MASH)4 recruiting
• High blood pressure4 recruiting
• Prostate cancer4 recruiting
• Multiple myeloma3 recruiting
• Parkinson disease3 recruiting
• Pulmonary arterial hypertension3 recruiting
• Sickle cell disease3 recruiting
• Stroke3 recruiting
• ALS (motor neurone disease)2 recruiting
• Aplastic anaemia2 recruiting
• Atrial fibrillation2 recruiting
• Autism2 recruiting
• Bipolar disorder2 recruiting
• Endometrial cancer2 recruiting
• Head and neck cancer2 recruiting
• Hepatitis B2 recruiting
• Hepatitis C2 recruiting
• Liver cirrhosis2 recruiting
• Melanoma2 recruiting
• Neuroblastoma2 recruiting
• Postural tachycardia syndrome (POTS)2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Aortic stenosis1 recruiting
• Brain metastases1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Coronary artery disease1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Duchenne muscular dystrophy1 recruiting
• Dystonia1 recruiting
• Familial hypercholesterolaemia1 recruiting
• Glioblastoma1 recruiting
• Gout1 recruiting
• HIV1 recruiting
• Hodgkin lymphoma1 recruiting
• Hydrocephalus1 recruiting
• Kidney cancer1 recruiting
• Lewy body dementia1 recruiting
• Liver and biliary tract cancer1 recruiting
• Mild cognitive impairment1 recruiting
• Multiple sclerosis1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Myocarditis1 recruiting
• Obesity1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Pompe disease1 recruiting
• Sarcoidosis1 recruiting
• Sarcoma1 recruiting
• Schizophrenia1 recruiting
• Spinal cord injury1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Completed

  mHealth Intervention for Pain Self Management

  NCT07332377· Virginia Commonwealth University· Source

• Completed

  Digital Pathology and AI for Liver Outcomes in MASLD (DPAILO-2)

  NCT06493253· PharmaNest, Inc· Source

• Recruiting

  Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

  NCT06699849· Phase 2· CSL Behring· Source

• Completed

  Clinical Validation of a Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer (VERIFI)

  NCT06947395· Immunovia, Inc.· Source

• Terminated

  A Study to Test Whether BI 1356225 Improves Impulsive Behavior in People With Opioid Use Disorder Who Are Taking Buprenorphine

  NCT06628622· Phase 1· Boehringer Ingelheim· Source

• Completed

  Sleep Extension to Improve Sleep Efficiency and QoL in HF With Preserved Ejection Fraction: the SLEEP-HF Pilot Study

  NCT06567925· Virginia Commonwealth University· Source

• Completed

  A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF:

  NCT06676072· Abbott Medical Devices· Source

• Completed

  IC14 for Treatment of Acute Decompensated Heart Failure

  NCT06556810· Phase 1/2· Implicit Bioscience· Source

• Completed

  Feasibility Study for the Comprehensive Overweight/Obesity Management Pre-Kidney Transplant (COMPKT) Program

  NCT06688825· Virginia Commonwealth University· Source

• Completed

  Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer

  NCT06947382· Immunovia, Inc.· Source

• Completed

  CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial

  NCT06439420· Phase 2· Virginia Commonwealth University· Source

• Completed

  A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis

  NCT06159725· Phase 1/2· Clarametyx Biosciences, Inc.· Source

• Completed

  Global Study of Del-desiran for the Treatment of DM1

  NCT06411288· Phase 3· Avidity Biosciences, Inc.· Source

• Completed

  Improving Access to Community-Based Occupations Via a Rideshare Training Program

  NCT06323850· Virginia Commonwealth University· Source

• Completed

  Integration of Neurofunctional Phenotyping Into Investigation of CBT4CBT for AUD

  NCT06190236· Virginia Commonwealth University· Source

• Completed

  Behavioral Exercise TRaining for Men Undergoing Androgen Depr Therapy for Prostate Ca

  NCT06250751· Virginia Commonwealth University· Source

• Completed

  The Effects of IL-1 Blockade on Inotrope Sensitivity in Patients With Heart Failure (AID-HEART)

  NCT06062966· Phase 1· Virginia Commonwealth University· Source

• Completed

  Feasibility Study: Educational Genetic Test Video

  NCT06166758· Virginia Commonwealth University· Source

• Completed

  Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1

  NCT06204809· Phase 1· PepGen Inc· Source

• Recruiting

  A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

  NCT06091254· Phase 3· Regeneron Pharmaceuticals· Source

• Completed

  WE Project: 2.0 Grassroots Wellness Coaching (Phase 2)

  NCT06172582· Virginia Commonwealth University· Source

• Completed

  CALM: Managing Distress in Malignant Brain Cancer

  NCT06180460· Virginia Commonwealth University· Source

• Completed

  The Effects of Passive Heat Therapy in Patients With Chronic Kidney Disease

  NCT05924919· Virginia Commonwealth University· Source

• Completed

  C-SMART: Cognitive Strategies, Mindfulness, and Rehabilitation Therapy for Patients With Primary Brain Tumors

  NCT05984667· Virginia Commonwealth University· Source

• Completed

  Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder

  NCT05886582· Phase 2· Virginia Commonwealth University· Source

• Completed

  SUBLOCADE Long-term Outcomes

  NCT05860959· Phase 4· Indivior Inc.· Source

• Completed

  Engaging Black Men in Colorectal Cancer Screening

  NCT05980182· Virginia Commonwealth University· Source

• Completed

  Genetic and Neural Factors in Alcohol-Related Cognition

  NCT03725345· Virginia Commonwealth University· Source

• Terminated

  Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®

  NCT05900050· Phase 2· Genfit· Source

• Completed

  Using Grassroots Wellness Coaching to Enhance Reach and Sustainability of Behavioral Weight Management

  NCT05544708· Virginia Commonwealth University· Source

• Terminated

  Antiretroviral Improvement Among Medicaid Enrollees

  NCT05477485· Virginia Commonwealth University· Source

• Recruiting

  Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

  NCT05727904· Phase 3· Iovance Biotherapeutics, Inc.· Source

• Completed

  Effectiveness of IVR Combined With Task-Specific Training on Hemiplegic Arm Function Following Stroke

  NCT05728866· Virginia Commonwealth University· Source

• Terminated

  A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications

  NCT05317078· Phase 1· Amgen· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

  NCT05721573· Phase 2/3· Abcuro, Inc.· Source

• Terminated

  Mitochondrial Derived Reactive Oxygen Species on Cardiovascular Health in Chronic Obstructive Pulmonary Disease (COPD)

  NCT05605548· Early phase 1· Virginia Commonwealth University· Source

• Completed

  Effect of Parenting With Positive Interven on Comm Inclusion for Military Connected and Dependents With Autism

  NCT05580432· Virginia Commonwealth University· Source

• Withdrawn

  Effects of Mindfulness Based Stress Reduction Intervention in Patients With Non-alcoholic Fatty Liver Disease

  NCT05130346· Virginia Commonwealth University· Source

• Completed

  ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)

  NCT05081245· Phase 2· MapLight Therapeutics· Source

• Completed

  Vitamin E Dosing Study

  NCT04801849· Phase 2· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Source

• Completed

  Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients

  NCT05479981· Phase 2· Avidity Biosciences, Inc.· Source

• Completed

  Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis

  NCT05180240· Phase 2· Cardiol Therapeutics Inc.· Source

• Completed

  Istradefylline for Parkinson Disease With Cognitive Impairment

  NCT05333549· Phase 2· Virginia Commonwealth University· Source

• Completed

  Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies

  NCT05225415· Phase 2· Cognition Therapeutics· Source

• Completed

  A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

  NCT05348785· Phase 2· Biogen· Source

• Completed

  Defining Endpoints in Becker Muscular Dystrophy

  NCT05257473· Virginia Commonwealth University· Source

• Terminated

  Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

  NCT05263492· Phase 2· Virginia Commonwealth University· Source

• Terminated

  Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

  NCT05305040· Phase 2/3· AlloVir· Source

• Completed

  A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

  NCT05198804· Phase 1/2· K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc· Source

• Completed

  Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir

  NCT05169580· Phase 1· Fulcrum Therapeutics· Source

Showing 50 of 91.

Conditions

Diseases this institution publishes on or runs trials for.

• Obesity103 works · 7 trials
• Heart failure100 works · 18 trials
• Fatty liver disease (MASLD/MASH)97 works · 17 trials
• Parkinson disease48 works · 6 trials
• Cystic fibrosis36 works · 8 trials
• Depression36 works · 0 trials
• Triple-negative breast cancer33 works · 0 trials
• Schizophrenia30 works · 1 trial
• Bipolar disorder27 works · 2 trials
• Sickle cell disease27 works · 9 trials
• Insomnia24 works · 1 trial
• Acute myeloid leukaemia22 works · 6 trials
• Hydrocephalus20 works · 4 trials
• Spinal cord injury17 works · 1 trial
• Myotonic dystrophy16 works · 11 trials
• Hepatitis C16 works · 4 trials
• Long COVID and ME/CFS12 works · 0 trials
• Myasthenia gravis11 works · 2 trials
• Myocarditis11 works · 2 trials
• Sarcoidosis9 works · 2 trials
• Ventricular tachycardia9 works · 2 trials
• Hidradenitis suppurativa7 works · 1 trial
• Lyme disease5 works · 0 trials
• Lewy body dementia5 works · 2 trials
• High blood pressure4 works · 5 trials
• Lichen planus4 works · 0 trials
• Aplastic anaemia3 works · 3 trials
• Neurofibromatosis type 13 works · 0 trials
• Giant cell arteritis3 works · 0 trials